Development of new intrathoracic therapies and biomarkers for pleural mesothelioma

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K09311
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 55040:Respiratory surgery-related
• Research Institution: Kitasato University
• Principal Investigator: Shiomi Kazu 北里大学, 医学部, 講師 (50398682)
• Co-Investigator(Kenkyū-buntansha): 江島 耕二 北里大学, 医学部, 准教授 (30327324) ; 小寺 義男 北里大学, 理学部, 教授 (60265733)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 胸膜中皮腫 / 胸腔内治療 / バイオマーカー / 免疫療法

Outline of Final Research Achievements

Using mouse models of pleural mesothelioma, we have established an experimental system to evaluate sustained release effect of Gemcitabine, a small molecule anticancer drug, administered intrapleurally together with gel.
Novel proteins that are candidates of biomarkers for mesothelioma were not identified by a shotgun proteomics approach using human mesothelioma tissue specimens. Therefore, using mouse model which is inoculated subcutaneouslly with mouse mesothelioma cell lines, we are trying to identify molecules which are differently expressed in tumor-infiltrating lymphocytes before and after administration of immune checkpoint inhibitors.

Free Research Field

呼吸器外科学

Academic Significance and Societal Importance of the Research Achievements

胸腔内腫瘍に対して薬物を効果的に作用させる治療法の開発は、胸膜中皮腫の予後を改善するために重要である。我々は、マウス胸腔内に抗癌剤を投与した際に徐放効果を正確に評価するための実験系を確立した。今後、この実験系を用い、種々のゲルとともに抗癌剤を胸腔内に投与し、最も有効な胸腔内治療法を検討する。本治療法は、腹腔内腫瘍に対しても利用できるため、多くのがん種で役立つ可能性がある。